Patricia A. Ganz

Patricia A. Ganz is a medical oncologist at the University of California, Los Angeles.[12]She specializes in cancer prevention and control research.[34]She is a member of division of cancer prevention.[4]

Patricia A. Ganz, MD, a medical oncologist, has been a member of the faculty of the UCLA School of Medicine since 1978 and the UCLA School of Public Health since 1992.[5]She is a pioneer in the assessment of quality of life in cancer patients and has focused much of her clinical and research efforts in breast cancer and its prevention.[6]She is a founding member of the National Coalition for Cancer Survivorship, and helped establish the widely accepted definition of cancer survivorship as someone living with cancer, from the time of diagnosis through the balance of life.[7]She is also a member of the Institute of Medicine, a component of the United States National Academy of Sciences.[7]She also served on the National Cancer Institute Board of Scientific Advisors and on the American Society of Clinical Oncology Board of Directors.[8]She also is active in clinical trials through the National Surgical Adjuvant Breast and Bowel Project.[9]

Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.

Mentions - Mentions are snippets of text that map to a person.

Docs - The number of documents that match to a person in Primer's corpus of news articles.

Full tech explainer here.

Create an article for Patricia A. Ganz on Wikipedia

Remember to check the sources and follow Wikipedia's guidelines.

UCLA Jonsson Comprehensive Cancer Center


  • 1


  • 536


  • 172


Recent events

Age Determines Symptoms Experienced In Some Breast Cancer Drugs

UCLA researchers analyzed the long-term outcomes in postmenopausal women who took the drugs anastrozole and tamoxifen--two widely used breast cancer treatments. They found that while both drugs proved safe and effective--with no effect on overall quality of life--the severity of some symptoms associated with the drugs' use were linked to age. "Both of these drugs are excellent and can reduce the risk for breast cancer recurrence in postmenopausal women with DCIS that is hormone receptor positive," said lead study author Dr. Patricia Ganz, director of the UCLA Jonsson Comprehensive Cancer Center's Prevention and Control Research program, in a news release.[1011]


Event Date